2.7.7.64	(3R)-1-(4-chlorobenzoyl)-N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)piperidine-3-carboxamide	compound (3R)-1-(4-chlorobenzoyl)-N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)piperidine-3-carboxamide preferentially binds to one site located in the proximity of the active center of the enzyme	254467	
2.7.7.64	2-(5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)oxybenzamide	-	255084	
2.7.7.64	2-(furan-2-yl)-N'-(indol-3-ylidenemethyl)quinoline-4-carbohydrazide	-	255135	
2.7.7.64	2-[(3As,7aR)-1,3-dioxo-3a,4,7,7a-tetrahydroisoindol-2-yl]-N-[4-(propan-2-ylsulfamoyl)phenyl]acetamide	-	255262	
2.7.7.64	2-[3-(trifluoromethyl)anilino]-1,3-thiazol-4-one	compound 2-[3-(trifluoromethyl)anilino]-1,3-thiazol-4-on preferentially binds to one site located in the proximity of the active center of the enzyme	255277	
2.7.7.64	3-(2-aminoethyl)-1-methylquinazoline-2,4(1H,3H)-dione	-	255341	
2.7.7.64	3-(trifluoromethyl)benzoic acid	-	255372	
2.7.7.64	ADP	at higher concentrations above 6 mM	13	
2.7.7.64	ATP	-	4	
2.7.7.64	diphosphate	-	17	
2.7.7.64	EDTA	-	21	
2.7.7.64	EDTA	complete inhibition	21	
2.7.7.64	ethyl 2,4-dimethyl-5-[(2R)-2-[4-(2-phenoxyethyl)piperazin-1-yl]propanoyl]-1H-pyrrole-3-carboxylate	-	255914	
2.7.7.64	hydrogen peroxide	inactivation, reactivation by reduction using cysteine or thioredoxin	1126	
2.7.7.64	methyl (2R)-2-[[2-(4-fluorophenyl)sulfanylacetyl]amino]-3-hydroxypropanoate	-	255952	
2.7.7.64	methyl(3-fluorophenyl)acetate	-	255981	
2.7.7.64	additional information	identification of structurally diverse scaffolds for the development of USP inhibitors by fragment library screening, selection of small molecule inhibitors with allosteric regulation sites, that inhibit both Leishmania major USP and UGP. Inhibitor binding kinetics, computational docking study, overview	2	
2.7.7.64	N-(2-methoxyethyl)-2-oxo-1,3-benzoxazole-3(2H)-carboxamide	-	256017	
2.7.7.64	nitric oxide	inactivation, reactivation by reduction using cysteine or thioredoxin	662